新朋股份(002328.SZ):金浦新興產業基金投資的西力科技已在科創板掛牌上市
格隆匯 3 月 18日丨新朋股份(002328.SZ)公佈,公司從上海金浦新興產業股權投資基金合夥企業(有限合夥)(“金浦新興產業基金”)獲悉,其投資的杭州西力智能科技股份有限公司(“西力科技”)已於2021年3月18日在上海證券交易所科創板正式掛牌上市,股票簡稱:西力科技,股票代碼:688616。
截止2021年3月18日,公司持有金浦新興產業基金股權比例為63.42%,金浦新興產業基金目前持有西力科技140.625萬股,佔該公司發行後總股本的0.94%,金浦新興產業基金須遵守西力科技首次公開發行股票(A股)招股説明書中披露的發行前股東自願鎖定和減持意向的相關承諾。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.